OncoMatch/Clinical Trials/NCT06332430
Intratumoral CAN2109 in Subjects With Solid Tumors
Is NCT06332430 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CAN2109 for solid tumor.
Treatment: CAN2109 — A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Unstable/inadequate cardiac function defined as: NYHA Class 3 or 4 congestive heart failure, uncontrolled hypertension, acute coronary syndrome within 6 months, clinically important cardiac arrhythmia, mean QTc > 480 ms
Unstable/inadequate cardiac function defined as follows: New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled hypertension, acute coronary syndrome within 6 months, clinical important cardiac arrhythmia, mean corrected QT (QTc) interval corrected for heart rate > 480 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06332430 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages